An Expanded Access Program for AM0010 (Pegilodecakin)

You may not be if

• Patient is in urgent need of therapy who fail to meet eligibility criteria for other clinical trials related to AM0010 (PEG-IL-10) can be considered for enrollment into this Expanded Access Program.
• Patient has advanced cancer in indications where preliminary anti-tumor efficacy of AM0010 has been demonstrated or where AM0010 mediated immune activation is likely to benefit the patient.
• Patient has failed or progressed on standard of care (SOC) systemic therapy
• Patient is refusing SOC therapy